Dr. Lori K. Ramirez, MD
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- University of Hawaii John A. Burns School of Medicine (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 314
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: University of Hawaii John A. Burns School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
UT license 7704079-1205
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Ogden Clinic Specialty Services LLC (132 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 314
- Services billed
- 4,548
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 1,050 | 166 |
| Established patient office or other outpatient visit, 20-29 minutes | 344 | 247 |
| Destruction of precancer skin growth, 1 growth | 271 | 206 |
| Biopsy of related skin growth, first growth | 62 | 58 |
| New patient office or other outpatient visit, 30-44 minutes | 55 | 55 |
| Destruction of precancer skin growth, 15 or more growths | 39 | 27 |
| Shaving of skin growth of body, arms, or legs, 0.5 cm or less | 29 | 26 |
| Established patient office or other outpatient visit, 30-39 minutes | 28 | 26 |
| Destruction of skin growth, 1-14 growths | 27 | 23 |
| Established patient office or other outpatient visit, 10-19 minutes | 18 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 17 companies reported 105 payments worth $14,437 in total to this clinician.
| Pfizer Inc. | $9,294 |
|---|---|
| Novartis Pharmaceuticals Corporation | $3,757 |
| UCB, Inc. | $436 |
| Leo Pharma Inc. | $320 |
| Galderma Laboratories, L.P. | $187 |
| AbbVie Inc. | $99.62 |
| Botanix Sb Inc | $72.77 |
| Sun Pharmaceutical Industries Inc. | $51.69 |
| Consulting Fee | $7,650 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $3,222 |
| Food and Beverage | $2,215 |
| Travel and Lodging | $1,349 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Mar 13, 2025 | Consulting Fee CIBINQO · Inflammation & Immunology | $4,500 |
| Novartis Pharmaceuticals Corporation Jul 26, 2025 | Consulting Fee COSENTYX · Dermatology | $3,150 |
| Pfizer Inc. Jun 23, 2025 | Compensation for services other than consulting (speaking, faculty) LITFULO · IMMUNOLOGY | $3,125 |
| Pfizer Inc. Feb 1, 2025 | Travel and Lodging CIBINQO · Inflammation & Immunology · travel to Rosemont, IL · in-kind | $724 |
| Pfizer Inc. Feb 1, 2025 | Travel and Lodging CIBINQO · Inflammation & Immunology · travel to Rosemont, IL · in-kind | $588 |
| Pfizer Inc. Apr 3, 2025 | Compensation for services other than consulting (speaking, faculty) CIBINQO · Inflammation & Immunology | $97.32 |
| Novartis Pharmaceuticals Corporation Jul 26, 2025 | Travel and Lodging COSENTYX · Dermatology · travel to SALT LAKE CITY, UT · in-kind | $37.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $107,010 in research payments for these studies, mostly to the institutions running them.
- A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients wi…
Novartis Pharmaceuticals Corporation - A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo
Sanofi US Services Inc. · Completed · NCT06015308
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.